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Minimally invasive Heller myotomy rates have increased, but little evidence is available regarding long 
term clinical and surgical outcomes. Our aim was to evaluate long term symptom improvement and 
medication resolution for patients undergoing minimally invasive Heller myotomy. 
Methods 
A single-institution database was retrospectively reviewed for patients undergoing laparoscopic Heller 
myotomy (LHM) or robotic Heller myotomy (RHM) during 2007-2018. Patients with primary HM followed 
by a Dor fundoplication were included. Demographics and surgical data were analyzed. Esophageal 
symptoms, testing, and medication use were collected preoperatively (pre-op), at 6-month (6-mo), 
12-month (12-mo), and long-term (LT; 12-mo+) follow-up. Analysis was performed using SPSS v.23.0, 
α=0.05. 
Results 
Eighty eight patients (RHM:N=66; LHM:N=22) were included. The majority were male (62.5%) and 
Caucasian (89.8%), with a mean BMI of 27.3. Two patients had an intraoperative esophageal perforation, 
each repaired with a non-eventful postoperative course. Mean follow-up time was 71 months overall, 75 
months [11-171 months] and 40 months [6-158 months] for LHM and RHM, respectively. All patients 
showed significant LT improvement of regurgitation, solid or liquid dysphagia, and Eckardt Score. 
Postoperative proton pump inhibitor (PPI) use was significantly lower at LT (LHM:31.3%, RHM:19.4%) 
compared to pre-op. 
Conclusion 
In this study, minimally invasive HM was a safe and effective treatment for achalasia symptom resolution 
in the long term. Therefore, in our experience, minimally invasive HM is a safe therapy that helps maintain 
symptom resolution. 
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Abstract
Introduction: Minimally invasive Heller 
myotomy (MIHM) rates have increased, but 
little evidence is available regarding long term 
(LT) clinical and surgical outcomes. Our aim 
was to evaluate LT symptom improvement 
and medication resolution for patients 
undergoing MIHM.
Methods: A single-institution database 
was retrospectively reviewed for patients 
undergoing laparoscopic Heller myotomy 
(LHM) or robotic Heller myotomy (RHM) 
during 2007-2018. Patients with primary 
HM followed by a Dor fundoplication were 
included. Demographics, surgical data 
and direct cost were analyzed. Esophageal 
symptoms, testing, and medication use were 
collected pre-operatively (pre-op), at 6-month 
(6-mo), 12-month (12-mo), and LT (15-mo+) 
follow-up. Analysis was performed using 
SPSS v.23.0, α=0.05.
Results: Eighty eight patients (RHM:N=66; 
LHM:N=22) were included. The majority 
were male (62.5%) and Caucasian (89.8%), 
with a mean BMI of 27.3. Two patients had 
an intraoperative esophageal perforation, each 
repaired with a non-eventful post-operative 
course. Mean follow-up time was 71 months 
overall, 75 months [11-171 months] and 40 
months [6-158 months] for LHM and RHM, 
respectively. All patients showed significant 
LT improvement of regurgitation, solid or 
liquid dysphagia, and Eckardt Score. Post-
operative proton pump inhibitor (PPI) use 
was significantly lower at LT (LHM:31.3%, 
RHM:19.4%) compared to pre-op.
Conclusion: In this study, MIHM was a safe 
and effective treatment for achalasia symptom 
resolution in the LT. Therefore, in our 
experience, MIHM is a safe therapy that helps 
maintain symptom resolution.
Introduction
Achalasia is a functional disorder of the 
esophageal body and lower esophageal 
sphincter (LES), resulting in a wide array 
of clinical symptoms.1,2 Although the cause 
and contributing factors to the development 
of achalasia are unknown, the resulting 
symptoms are well detailed and include 
dysphagia, regurgitation, chest pain and 
cough. Several treatment options are available 
for achalasia, but Heller myotomy (HM) is 
the accepted definitive surgical treatment, due 
to its recognized long term (LT) benefits in 
symptom resolution, medication resolution, 
and quality of life improvements.3,4 Since 
the first HM was performed over 100 years 
ago, tremendous advancements have been 
made in the procedure, including a transition 
away from an open approach to a minimally 
invasive approach.5 Laparoscopic, and more 
recently, robotic approaches are being adopted 
because minimally invasive approaches 
have been shown to decrease post-operative 
complications and hospital length of stay.6 
Minimally invasive surgery (MIS) has also 
been shown to reduce operating time, reduce 
re-bleeding, and decrease mortality in a 
wide spectrum of specialties ranging from 
neurosurgery to orthopaedics.7,8 In addition to 
positive post-operative outcomes, dysphagia 
rates, the leading sign of successful achalasia 
treatment, have been shown to decrease 
significantly after minimally invasive HM 
(MIHM).9,10 This is an important finding 
because progressive dysphagia leads to an 
extremely poor quality of life in achalasia 
patients if left untreated.11
Few studies have examined the benefits of 
short-term and LT outcomes after laparoscopic 
HM. Other authors have described benefits 
in regards to lower rates of dysphagia and 
heartburn, as well as improved swallowing 
status.12,13 Still, fewer authors have looked 
at robotic HM, with small cohorts ranging 
from 14-56 patients.14,15 Therefore, despite 
the data that exist on MIS benefits for 
surgical procedures in general, there is a 
lack of research substantiating feasibility 
and LT results after both minimally invasive 
Heller approaches, especially those with 
a long follow-up time. Given the efficacy 
of minimally invasive approaches in other 
surgical fields, the aim of our study was to 
evaluate short and LT symptom improvement 
in patients who underwent MIHM. 
Methods
A single institution database was 
retrospectively reviewed for patients who 
underwent either a robotic-assisted (RHM) or 
laparoscopic Heller myotomy (LHM) between 
2007 and 2018. Only adult patients who had 
a diagnosis of achalasia and who underwent 
primary HM followed by a Dor fundoplication 
were included in this study. Three patients 
underwent Nissen or Toupet fundoplication 
and were excluded. The technique for HM 
followed by Dor fundoplication comprises 
of esophageal mobilization, release of 
esophageal and gastric muscles fibers, 
followed by a 180º anterior fundoplication. 
The goal of the procedure is to facilitate LES 
function and resolve achalasia.16 All surgeries 
in this cohort were performed by the same 
surgeon. Exclusion criteria included any 
patient with other esophageal disease, such 
as ineffective dysmotility or malignancy. A 
diagnosis of achalasia was determined by 
the Chicago Classification of esophageal 
dysmotility standards, according to pre-
operative esophageal manometry testing.17 
Demographics, such as gender, age, race, 
body mass index (BMI), and smoking history 
were collected. Patient health information 
such as pre-operative esophageal symptoms 
and testing, medication use, medical history, 
and pre-operative comorbidities were 
collected. Pre-operative esophageal testing 
included esophagogastroduodenoscopy 
(EGD), barium esophagram, manometry, 
and pH testing. Esophageal symptoms were 
analyzed using a validated esophageal score,18 
and analysis was based on a composite 
of mean scores. Surgical data comprised 
surgical approach, operating time, blood loss, 
intraoperative complications, and length of 
stay. Post-operative complications, including 
bleeding, ileus, and others were recorded. 
Frequency of esophageal symptoms and 
Eckardt score were collected using a validated 
intra and extra esophageal symptom survey 
pre-operatively (pre-op), and at 6-month (6-
mo), 12-month (12-mo), and LT (15+ months) 
follow-up. 
Data are presented as frequency for 
categorical data, or as median or mean, for 
continuous data according to normality. 
Descriptive statistics were calculated for the 
cohort, and comparisons were made using 
t-tests or chi-square testing. The Sign test with 
Bonferroni correction was used for additional 
evaluation of symptoms improvement over 
time compared to the baseline.19 Statistical 
analysis was performed using SPSS v.25.0, 
with α=0.05. 
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Results
Eighty-eight patients underwent MIHM 
followed by Dor fundoplication (RHM: N=66; 
LHM: N=22) and met the inclusion criteria 
for the study. The mean age was 53.1± 17.6 
years and the mean BMI was 27.3 kg/m2. 
Over half of patients were male (62.5%) and 
Caucasian (89.8) (Table 1).
Table 2 shows intra-operative findings. All 
hiatal hernias were repaired at the time of 
surgery. A majority of patients had minimal 
(<50mL) blood loss, and two patients had an 
intra-operative complication. One patient in 
each group had an intra-operative esophageal 
perforation, which was repaired with a 
non-eventful post-operative course. Post-
operatively, length of stay was 2.14 ± 2.98 
days overall, 1.87 ± 2.68 days for the robotic 
approach, and 3.29 ± 3.9 for the laparoscopic 
approach (p=0.203). Post-operative 
complications occurred in four patients 
overall, three with post-operative bleeding, 
and one with post-operative ileus. 
Overall symptom scores improved over 
time, along with consistent improvement in 
Eckardt score, as shown in Table 3. Table 4 
demonstrates that symptom improvement 
from baseline was significant in all symptoms, 
with dramatic improvement in solid 
dysphagia from baseline to LT (p<0.001). 
Whether patients had laparoscopic or robotic 
procedure, there were no differences in post-
operative symptom scores. 
Mean LT follow-up time was 70 months ± 
47.07. Follow up ranged from 11-171 months 
in our cohort, with over a third of patients 
having LT follow up data over 4 years (N=31). 
Dilation rates and recurrence of objective 
GERD on upper gastrointestinal imaging 
(UGI) were low in this cohort. Overall, 11 
patients (12.5%) underwent post-operative 
dilation, with three of them requiring multiple 
procedures. Of the 11 patients dilated, two 
had evidence of peptic stricture and responded 
well to dilation and proton pump inhibitor 
therapy. In the remaining nine, those with 
dilated esophagus and angulation were 
dilated with a 20mm balloon. No patients 
had incomplete myotomy by manometry. 
The earliest dilation happened at least seven 
months after the surgery. UGI was performed 
at one year in 57 (65%) patients. Only three 
patients were found to have objective GERD 
diagnosed on post-operative UGI (5.2%), 
whereas two patients had asymptomatic 
recurrence of hiatal hernia. Use of post-
operative PPI was also reduced to just 23% of 
patients reporting PPI use, compared to 49% 
at baseline (Table 5). 
Discussion
This study demonstrates the safety and 
efficacy of MIHM. Our cohort of 88 patients 
had a less than 4.5% complication rate, 
with low rates of post-operative dilation. 
A significant number of patients reported 
improvement symptoms and heartburn scores 
in the LT. Furthermore, over 50% of the 
patients who reported pre-operative PPI use 
were able to stop taking these medications 
post-operatively. 
The demographics of our cohort, including 
race, gender, BMI, and age are similar to those 
reported in the current HM literature.16,20,21 
Conversely, our mean operative time of 190 
minutes was slightly longer than that reported 
in the literature (range:89-141 min).20,22 In 
the current study, data were collected from 
an academic medical center where residents 
and students often play a role in the operation. 
This may have contributed to the increased 
length of OR time. Our average length of stay 
was 2.14 days which falls within the expected 
range of 1-4.3 days.19,22 
The reported overall complication rates for 
MIHM range from 1.8-6.3%.20,21 Esophageal 
perforation is considered to be the most 
prevalent and serious complication of MIHM. 
In our study, only two patients (2.3%) 
suffered esophageal perforations. In both of 
these instances, perforations were repaired 
intraoperatively and patients had an otherwise 
unremarkable post-operative course. This 
is within the reported perforation rates in 
the literature ranging from 1-13% with one 
study citing the esophageal perforation rate 
as high as 33%.23 Mortality rates following 
perforation have been reported to be as high 
as 40%.24-27 The low rate of perforations 
in our cohort, coupled with a significant 
improvement in esophageal symptom scores, 
supports that MIHM is a safe and efficacious 
treatment for achalasia. 
An important marker of success following 
surgical treatment of achalasia is the 
resolution of dysphagia and other esophageal 
symptoms.9,10 Our study demonstrated that 
MIHM provided resolution of esophageal 
symptoms, including dysphagia, heartburn, 
regurgitation, and cough, evaluated at LT. In a 
LT study by Jeansonne et al., which evaluated 
Table 1.
Demographics and pre-operative characteristics of patients undergoing minimally invasive Heller 







N % N % N %
Female 33 37.5 21 31.8 12 54.5
Male 55 62.5 45 68.2 10 45.5
Age – years (mean ± SD) 53.1 ± 17.6 51.4 ± 16.5 57.9 ± 19.8
Race
Caucasian 79 89.8 57 86.4 22 100
AA 3 3.4 3 4.5 0 0
Other 3 3.4 3 4.5 0 0
Pre-op BMI kg/m2 27.3 ± 4.6 27.2 ± 4.6 28.5 ± 3.6
Pre-op Eckardt Score 4.4 ± 2.5 4.2 ± 2.8 4.4 ± 2.8
Overall Follow-up (months) 70.1 ± 47.0 40 (6 -158) 75 (11 - 171)
RHM Robotic-assisted Heller Myotomy; LHM Laparoscopic Heller Myotomy; Pre-op preoperative;  
AA African American
Table 2.
Intra-operative and peri-operative data on patients undergoing minimally invasive Heller myotomy. 
Comparisons between groups were made using Chi-square analysis or Wilcoxon rank sum test.
Overall RHM LHM p value
Operative Hiatal Hernia Present 10 (11.4%) 7 (10.6%) 3 (13.6%) 0.521
OR Time (min) 190 ± 48.32 193.0 ± 48.4 175.2 ± 48.1 0.931
Blood Loss (ml) 18.83 ± 22.30 15.6 ± 19.2 30.56 ± 29.7 0.203
LOS 2.14± 2.98 1.78 ± 2.5 3.29 ± 3.9 0.059
RHM Robotic-assisted Heller Myotomy; LHM Laparoscopic Heller Myotomy; LOS Length of Stay
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esophageal symptoms, 95% of patients who 
underwent MIHM demonstrated satisfaction 
with their operation, over a follow-up period 
of 10 years.12 Patients reported symptom 
improvement in dysphagia and cough at short- 
and LT follow-up, when compared to baseline 
(p<0.05). Improvement was not significant at 
LT follow-up in other esophageal symptoms 
such as heartburn, chest pain, regurgitation 
or asthma (p>0.05). At 10-year follow-up, 
62.5% of patients reported a lower symptom 
score for dysphagia when compared to the 
baseline. Whereas in our study, 98% of our 
patients reported improved dysphagia rates at 
LT, compared to baseline. Although Jeansonne 
et al. indicated the effectiveness of MIHM 
given the robust LT symptom resolution rates, 
their study was limited by a sample size of 
only 17 patients.12 The difference in sample 
size between the two studies (N=88 vs. N=17) 
may have contributed to the variable rates of 
symptom resolution; however, both studies 
ultimately corroborate the efficacy of MIHM. 
In a study of over 200 patients, 
Krishnamohan. et al., evaluated the severity 
and frequency of dysphagia of patients after 
MIHM using validated questionnaires.13 The 
questionnaires were able to capture robust 
data on dysphagia variability. The authors 
stated a significant decrease in dysphagia post-
operatively, with a third of patients (N=80) 
reporting complete resolution of dysphagia at 
6.4 years follow-up. Additionally, swallowing 
difficulty was further classified into dysphagia 
for liquids 31% (50/161) or solids 92.5% 
(149/161). These results were much higher 
than our LT dysphagia rates, which could be 
due to the variation in surgery received by 
the patients. In some cases, no fundoplication 
was performed (N=23;4.6%). The surgeon’s 
preference for the type of fundoplication also 
varied between Toupet (N=268) and Dor 
(N=209). 
Our patients demonstrated no difference 
between LHM and RHM in symptom 
resolution. Similar results are seen when both 
minimally invasive procedures, laparoscopy 
and robotic-assisted, were evaluated 
independently. A 2004 study by Ruurda et al, 
sought to gather data on symptom resolution 
for a small group of 14 patients undergoing 
robotic HM (RHM). They found that 86% 
(12/14) of patients reported dysphagia relief 
after the procedure, whereas 14% (2/14) 
reported heartburn, with a mean follow-up 
time of only 11 months. Another study of 73 
patients who underwent RHM, showed that 
96% reported their swallowing status to be 
good/excellent, with little information about 
other symptom resolution.28 
Although HM is the gold standard treatment 
for achalasia, new alternatives have emerged 
including per oral endoscopic myotomy 
(POEM). POEM is a natural orifice 
intervention for achalasia, showing mixed 
results in the short and LT compared to 
HM.29,30 POEM is praised for its short term 
efficacy, low post-operative pain scores, and 
quick return to normal function. However, 
LT efficacy of POEM remains debated.31,32 A 
systematic review comparing POEM to HM 
in the LT, noted that POEM has a much higher 
incidence of pathological reflux, which could 
potentially lead to complications such as 
Barrett’s esophagus.30 Additionally, one series 
noted the high incidence of intraoperative 
complications including burns and small 
perforations (21%) and symptomatic 
capnoperitoneum (11%).33 This study also 
echoed the high incidence of GERD following 
POEM, with a reported 38% of their patient 
population experiencing GERD. Although our 
focus was not to compare POEM to HM, our 
objectively measured GERD rates were much 
lower at 5.2% following HM, when compared 
to POEM. 
Freedom from medication after surgery is 
an additional important marker of success 
in these patients. We found that objectively 
measured reflux in our patient population was 
5.7% at 1-year follow-up. PPI use at 1-year 
follow-up was 2.8%, which is lower than 
our UGI objectively measured GERD. At LT 
follow-up 23% of our cohort reported PPI use. 
This is much lower than reported rates in the 
literature. Medication use rates after MIHM 
has been reported to range from 25% to 66% 
of patients taking anti-reflux medications 
such as antacids, Histamine H2-receptor 
antagonists (H2 blockers), calcium channel 
blockers (CCB) or PPI post-operatively.34,35 
Table 3.
Overall mean symptom scores over time for patients who underwent minimally invasive Heller 
myotomy.
Pre-op 6-mo 12-mo LT
Heartburn 1.631 0.360 0.412 0
Regurgitation 2.594 0.230 0.118 0
Solid Dysphagia 3.452 0.633 0.500 0.02
Liquid Dysphagia 2.833 0.298 0.194 0
Eckardt Score 4.398 0.760 0.560 0.315
Pre-op preoperative; 6-mo 6 months follow-up; 12-mo 12 months follow-up; LT Long-term follow-up
Table 4.
Symptom score improvement over time in patients who underwent minimally invasive Heller myotomy. 
Repeated measures ANOVA was used to test for symptom score improvement.
6mo (n=43) 12mo (n=44) LT (n=54)
Symptom %Improved p %Improved p %Improved p
Heartburn 54 <0.001 53 <0.001 61 <0.001
Regurgitation 78 <0.001 80 <0.001 79 <0.001
Solid Dysphagia 93 <0.001 77 <0.001 98 <0.001
Liquid Dysphagia 90 <0.001 89 <0.001 84 <0.001
Any Dysphagia 62 <0.001 70 <0.001 96 <0.001
Table 5.
Long term proton pump inhibitor resolution in patients who underwent minimally invasive Heller 
myotomy.
Pre-op 6-mo 12-mo LT
PPI use N % N % N % N %
Overall 36 49 10 18 1 2.8 11 23
LHM 11 61 3 19 0 0 5 31
RHM 25 45 7 18 1 3.8 6 19
Preop preoperative; 6-mo 6 months follow-up; 12-mo 12 months follow-up; LT Long-term follow-up,  
RHM Robotic-assisted Heller Myotomy; LHM Laparoscopic Heller Myotomy
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A study of over 500 patients who underwent 
MIHM showed 66% of patients (159/241) 
were taking antacids, Histamine 2 blockers, 
or PPI at LT follow-up (mean 6.4 years).13 
While these authors used objective testing 
in the form of pre-operative manometry to 
diagnose achalasia, there was no objective 
testing routinely obtained post-operatively. In 
a different cohort, 25% of patients had severe 
enough reflux symptoms post operatively to 
require PPI therapy.35 
Perry et al., evaluated the difference in 
medication use between MIS approaches, 
and found 56% of robotic patients and 80% 
of laparoscopic patients required medication 
for reflux at LT follow-up.14 While they cite 
their PPI use as “very high,” the authors point 
to a need for objective testing to determine 
if the symptoms are truly a result of acid 
reflux. Others have reported more descriptive 
breakdowns, with 41%, 7% and 2% of 
patients post-operatively taking PPIs, CCBs, 
and Nitroglycerine, respectively.36 In our 
patient cohort, only 23% of patients reported 
taking PPIs at LT follow-up, versus 49% at 
pre-op. 
Our study has several limitations, including 
its retrospective nature and the limited sample 
size. However, this is one of the largest 
studies to our knowledge and with an overall 
response rate of 61% (54/88) at LT follow-
up, we found consistent data collection in 
our patient population. In order to limit the 
effects of recall bias, we routinely collected 
symptom scores at 3-, 6- and 12-months 
post-operatively and established these time 
points as our standard of care. The survey we 
provided pre- and post-operatively at intervals 
of 3-, 6-, 12-month, and LT, is a significant 
assessment of a spectrum of esophageal and 
extra-esophageal symptoms, and has been 
validated in previous publications.19 Further, 
the survey is a good measurement tool for 
reported symptoms and is clinically relevant 
to our patient population. Additionally, 
we have pertinent information on reported 
dysphagia, which is the most important 
symptom relating to esophageal dysmotility, 
and our survey gathers robust data on 
dysphagia resolution. Due to the long duration 
of follow-up in this study, patients who were 
categorized as “lost to follow-up” were 
elderly and died of unrelated causes. LT 
objective measurement should be collected in 
order to determine if the PPI use is related to 
symptomatic GERD, or prescribed by another 
specialty due to reasons unrelated to GERD.37
In conclusion, this study demonstrates 
the efficacy of MIHM in symptom relief 
and medication freedom for patients with 
achalasia. MIHM provides significant 
symptom relief in both the short-term and 
LT along with significant reduction in use of 
anti-reflux medications. Given the feasibility 
and safety of both laparoscopy and the robotic 
platform for a MIHM, either approach can 
be used and should be based on surgeon 
preference. 
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